JP2021523213A5 - - Google Patents
Info
- Publication number
- JP2021523213A5 JP2021523213A5 JP2020564674A JP2020564674A JP2021523213A5 JP 2021523213 A5 JP2021523213 A5 JP 2021523213A5 JP 2020564674 A JP2020564674 A JP 2020564674A JP 2020564674 A JP2020564674 A JP 2020564674A JP 2021523213 A5 JP2021523213 A5 JP 2021523213A5
- Authority
- JP
- Japan
- Prior art keywords
- icos
- cells
- seq
- agonist
- antibody
- Prior art date
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671181P | 2018-05-14 | 2018-05-14 | |
| US62/671,181 | 2018-05-14 | ||
| US201862679346P | 2018-06-01 | 2018-06-01 | |
| US62/679,346 | 2018-06-01 | ||
| US201862750026P | 2018-10-24 | 2018-10-24 | |
| US62/750,026 | 2018-10-24 | ||
| US201962827312P | 2019-04-01 | 2019-04-01 | |
| US62/827,312 | 2019-04-01 | ||
| PCT/US2019/032184 WO2019222188A1 (en) | 2018-05-14 | 2019-05-14 | Methods of treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523213A JP2021523213A (ja) | 2021-09-02 |
| JP2021523213A5 true JP2021523213A5 (https=) | 2022-05-20 |
| JPWO2019222188A5 JPWO2019222188A5 (https=) | 2022-05-20 |
Family
ID=66690990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564674A Pending JP2021523213A (ja) | 2018-05-14 | 2019-05-14 | 癌を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11292840B2 (https=) |
| EP (1) | EP3793598A1 (https=) |
| JP (1) | JP2021523213A (https=) |
| CN (1) | CN112703012A (https=) |
| WO (1) | WO2019222188A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| CA2890346A1 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| EP2945652B1 (en) | 2013-01-18 | 2021-07-07 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| US20200024351A1 (en) * | 2017-04-03 | 2020-01-23 | Jounce Therapeutics, Inc. | Compositions and Methods for the Treatment of Cancer |
| EP3870610A1 (en) * | 2018-10-24 | 2021-09-01 | Jounce Therapeutics, Inc. | Methods and compositions for the treatment of cancer and infectious diseases |
| EP4058593A4 (en) | 2019-11-12 | 2023-11-15 | Foundation Medicine, Inc. | METHODS FOR DETECTING A FUSION GENE ENCODING A NEO-ANTIGEN |
| JP2023510847A (ja) * | 2020-01-13 | 2023-03-15 | ジャウンス セラピューティックス， インク． | 癌の治療方法 |
| AU2021260553A1 (en) * | 2020-04-20 | 2022-10-20 | Jounce Therapeutics, Inc. | Compositions and methods for vaccination and the treatment of infectious diseases |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| CN112807425A (zh) * | 2021-01-14 | 2021-05-18 | 南方医科大学深圳医院 | 一种tTIM融合蛋白疫苗、制备方法及应用 |
| US20220396623A1 (en) | 2021-05-18 | 2022-12-15 | Kymab Limited | Uses of anti-icos antibodies |
| WO2022272309A1 (en) | 2021-06-25 | 2022-12-29 | Foundation Medicine, Inc. | Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| JP2025160816A (ja) * | 2024-04-10 | 2025-10-23 | イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド | 古典的ホジキンリンパ腫に対する併用療法 |
| CN118516308B (zh) * | 2024-07-22 | 2024-10-22 | 深圳市中佳生物医疗科技有限公司 | 免疫调节剂在制备增强nk细胞毒性作用的产品中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| ES2612914T3 (es) | 2011-03-31 | 2017-05-19 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos dirigidos contra Icos y usos de los mismos |
| CA2889182A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| SG11201506920QA (en) | 2013-03-15 | 2015-09-29 | Bristol Myers Squibb Co | Ido inhibitors |
| TWI719970B (zh) | 2015-03-23 | 2021-03-01 | 美商永斯醫療股份有限公司 | 針對ｉｃｏｓ之抗體 |
| EP3365372A1 (en) | 2015-10-22 | 2018-08-29 | Jounce Therapeutics, Inc. | Gene signatures for determining icos expression |
| WO2018029474A2 (en) * | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| KR20260030924A (ko) | 2016-08-09 | 2026-03-06 | 키맵 리미티드 | 항-icos 항체 |
-
2019
- 2019-05-14 WO PCT/US2019/032184 patent/WO2019222188A1/en not_active Ceased
- 2019-05-14 EP EP19728206.4A patent/EP3793598A1/en not_active Withdrawn
- 2019-05-14 CN CN201980047070.3A patent/CN112703012A/zh active Pending
- 2019-05-14 US US16/411,744 patent/US11292840B2/en active Active
- 2019-05-14 JP JP2020564674A patent/JP2021523213A/ja active Pending
-
2022
- 2022-03-31 US US17/709,712 patent/US20220332823A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523213A5 (https=) | ||
| Ishikawa et al. | Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with I g G 1 antibody in patients with gastric or colorectal cancer | |
| Makita et al. | Clinical development of anti‐CD 19 chimeric antigen receptor T‐cell therapy for B‐cell non‐Hodgkin lymphoma | |
| JP5665702B2 (ja) | Ｎｋ細胞増強化合物を使用する治療抗体の有効性を増大させる方法および組成物 | |
| US20230277591A1 (en) | Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia | |
| Goldwater et al. | A phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects | |
| JPWO2019222188A5 (https=) | ||
| KR20190123749A (ko) | 항-tigit 항체 | |
| KR20150042784A (ko) | Ｃａｒ의 항-종양 활성에 대한 독성 관리 | |
| Dokouhaki et al. | Adoptive immunotherapy of cancer using ex vivo expanded human γδ T cells: A new approach | |
| RU2012134369A (ru) | Биомаркеры иммуномодулирующих эффектов у людей, подвергнутых лечению антиметаллами против cd200 | |
| CN109385403A (zh) | 靶向gpc3的car nk细胞 | |
| WO2016069589A1 (en) | Treatment of pediatric bcp-all patients with an anti-kir antibody | |
| Magalhaes et al. | CD19 chimeric antigen receptor T cells from patients with chronic lymphocytic leukemia display an elevated IFN-γ production profile | |
| WO2017205213A1 (en) | Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer | |
| CN110520539A (zh) | 预测抗癌药的临床结果的方法 | |
| Mond et al. | SURFACE ANTIGENS OF IMMUNOCOMPETENT CELLS: III. IN VITRO STUDIES OF THE ROLE OF B AND T CELLS IN IMMUNOLOGICAL MEMORY | |
| Ma et al. | Automatic generation of lymphocyte heterogeneity: Division‐dependent changes in the expression of CD27, CCR7 and CD45 by activated human naive CD4+ T cells are independently regulated | |
| Nelson et al. | TT hybridoma product specifically suppresses tumor immunity. | |
| US20240207311A1 (en) | Tumor infiltrating lymphocytes therapy | |
| Luo et al. | Natural Killer Cell‐Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications | |
| CN116963746A (zh) | 选择性靶向cd6高细胞并降低teff细胞的活性的方法 | |
| Zhang et al. | Enhancement of B7-H3 chimeric antigen receptor-T cell efficacy via the coexistence effect of IL-7, IL-15 and CCL19 for pancreatic and lung xenograft tumors | |
| CN115724979B (zh) | 一种多功能重组抗体及其制备方法和应用 | |
| CN120904358B (zh) | 一种新型il-15融合蛋白及其应用 |